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bstract
bjectives:  To qualitatively evaluate late dynamic contrast phases, 10, 20 and 30 min, after administration of Gd-EOB-DTPA with regard to biliary
xcretion in patients presenting with elevated liver enzymes without clinical signs of cirrhosis or hepatic decompensation and to compare the visual
ssessment of contrast agent excretion with histo-pathological fibrosis stage, contrast uptake parameters and blood tests.
ethods:  29 patients were prospectively examined using 1.5 T MRI. The visually assessed presence or absence of contrast agent for each of five
natomical regions in randomly reviewed time-series was summarized on a four grade scale for each patient. The scores, including a total visual
core, were related to the histo-pathological findings, the quantitative contrast agent uptake parameters, expressed as KHep or LSC N, and blood
ests.
esults:  No relationship between the fibrosis grade or contrast uptake parameters could be established. A negative correlation between the visual
 sub-ssessment and alkaline phosphatase (ALP) was found. Comparing a
ynamic parameters did not add any additional significant correlation.
onclusions:  No correlation between visually assessed biliary excretion of
as found. A negative correlation between the visual assessment and alkali
 2015 The Authors. Published by Elsevier Ltd. This is a
http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations: Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylenetriaminepen
ontrast Enhanced Magnetic Resonance Imaging; LSC N, normalised liver-to-spleen
LP, alkaline phosphatase; NAFLD, non-alcoholic fatty liver disease; PSC, primary 
AT deficiency, 1-antitrypsin deficiency; DILI, drug induced liver injury; MANA, m
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sensitivity encoding (SENSE).
All subjects received a bolus injection of Gd-EOB-DTPA0 B. Norén et al. / European Journ
.  Introduction
With the introduction in 2004 of the hepatocyte specific
ontrast agent, Gd-EOB-DTPA (Primovist® Bayer Schering
harma, Berlin, Germany) a possible agent for demonstrating
lterations in signal intensity (SI) related to histo-pathological
hanges in patients with chronic liver disease (CLD) and also
valuating liver function was present. Approximately 50% of
he administered dose will be transported through the hepato-
ytes and excreted into the bile and the remaining 50% through
he kidneys. Focus has been on the uptake of Gd-EOB-DTPA in
he hepatocytes and pathophysiological conditions linked to that
nd a number of reports, including results from both animal and
uman studies, have been published. A correlation between con-
rast uptake and histo-pathological scoring of fibrosis has been
escribed [1–7], and since the prognosis of CLD largely depends
n the extent and progression of liver fibroisis the results may
ndicate the potential of dynamic contrast enhanced (DCE) MRI
s a non invasive tool in the assessment of fibrosis.
There are also reports evaluating alterations in biliary and
enal excretion in patients with diffuse liver disease. Tamada
t al. made a qualitative analysis to visually assess the biliary
xcretion and found a significantly delayed biliary excretion in
irrhotic patients compared to a control group. They also found
hat the enhancement effects measured as the relative enhance-
ent before and after contrast administration were significantly
igher in the cirrhotic liver than those of normal liver when
ssessed in the renal medulla and portal vein 20 min after the
ontrast infusion [8].
Tschirch et al. also made a qualitative assessment of the
isualization of different parts of the biliary ducts in cirrhotic
atients. Only 40% of the patients showed an overall sufficient
mage quality for anatomical diagnosis 30 min after contrast
dministration. They found a cut-off value of 30 mol/L for
otal bilirubin for insufficient visualization of the biliary tree for
natomical diagnosis 20 min after contrast administration [9].
Recently Dahlqvist Leinhardt et al. have proposed a
rocedure for quantifying the hepatocyte-specific uptake of Gd-
OB-DTPA. Based on the normalized signal intensity (SI),
ormalized liver-to-spleen contrast ratios (LSC N) were cal-
ulated at 10 min (LSC N10) and 20 min (LSC N20) and the
ontrast uptake rate (KHep) was calculated by using a phar-
acokinetic two-compartment model of the liver and spleen
10].
Applying this novel quantification procedure prospectively
n a group of patients referred for evaluation of elevated serum
lanine aminotransferase (ALT) and/or alkaline phosphatase
ALP), but without signs of liver cirrhosis in laboratory tests
r at physical examination, the main finding was that liver fibro-
is stage strongly influences the hepatocyte-specific uptake of
d-EOB-DTPA [11].
The purpose of this prospective study was to compare the
isual assessment of the contrast elimination via the bile ducts
ith (1) the histo-pathological fibrosis scoring, (2) the quantified
ptake of Gd-EOB-DTPA defined as KHep and LSC N (10 and
0 min), and (3) results from the liver and renal blood tests in
rder to determine the extent of possible co-variation.
(
uadiology Open 2 (2015) 19–25
.  Materials  and  methods
.1.  Subjects
In this prospective study, 29 patients were studied. The group
onsisted of 16 males (median age: 37, range: 20–57 years)
nd 13 females (median age: 60, range: 28–78 years). They
ere referred for evaluation of elevated serum ALT and/or ALP
evels. Physical examination and laboratory tests revealed no
igns of liver cirrhosis. Three patients were symptomatic (one
ith episodes of cholangitis and two with jaundice) while the
emaining 26 were asymptomatic. Two male patients had a
edian weekly alcohol consumption exceeding 140 g (192 g and
48 g respectively).
The diagnostic work-up resulted in the following definite
r plausible causes of elevated liver enzymes: non-alcoholic
atty liver disease (NAFLD) in 8 subjects, primary sclerosing
holangitis (PSC) in 7 subjects, hepatitis C (HCV) in 4 sub-
ects, autoimmune hepatitis (AIH) in 6 subjects, primary biliary
irrhosis (PBC) in 1 subject, 1-antitrypsin deficiency (AAT
eficiency) in 1 subject and drug induced liver injury (DILI)
ue to thioguanine in 1 subject. In the remaining one case, no
iagnosis could be determined by liver biopsy.
Demographic variables, clinical diagnosis, results from liver
nd renal function tests are presented in Table 1.
The study was approved by the regional ethics commit-
ee in Linköping, Sweden, registration number M72-07 T5-08.
atients participated in this study after their informed consent
as obtained.
.2.  Liver  biopsy  and  histo-pathology
Liver biopsy was performed on the same day immediately
fter the MR-examination on an outpatient basis using a 1.6 mm
iopince needle (Medical Device Technologies Inc., FL, USA)
n order to assess the histological severity of the underlying liver
isease, to confirm the plausible diagnosis or, in the case with the
ingle patient in whom prior diagnostic work-up was negative,
o elucidate the reason for the elevated liver enzymes. Biopsies
ere graded and classified according to the Batts and Ludwig
ystem, i.e. fibrosis was staged as: no fibrosis (F0), portal fibrosis
F1), periportal fibrosis (F2), septal fibrosis (F3) and probable or
bvious cirrhosis (F4). [12]. All biopsies were read by the same
iver pathologist, who was blinded to patient details and the MR
xamination results.
.3.  Data  acquisition
The data were acquired as previously described [10,11].
 1.5 T Achieva MR-scanner (Philips Healthcare, Best, The
etherlands) was used together with a phase-array body coil
ith 16 coil elements. Single breath-hold symmetrically sam-
led two-point Dixon 3D images [11] were acquired with0.025 mmol/kg) administered intravenously at a rate of 1 mL/s
sing a power injector (Medrad Spectris Solaris, Pittsburgh,
B. Norén et al. / European Journal of Radiology Open 2 (2015) 19–25 21
Table 1
Demographic variables, clinical diagnosis and results from liver and renal function tests.
Plausible diagnosis
prior to liver biopsy
Age
Mean ± SD
Sex BMI
Mean ± SD
Bilirubina ASTb ALTc ALPd GGTe Kreatininf
Female No
of subjects
Male No
of subjects
NAFLD 49.5 ± 14.9 4 4 28.7 ± 3.4 10.1 ± 3.1 0.7 ± 0.2 1.4 ± 1.1 1.4 ± 0.8 1.4 ± 1.3 74.6 ± 17.3
PSC 42.0 ± 20.0 2 5 24.6 ± 3.2 10.4 ± 2.9 1.1 ± 0.6 2.1 ± 1.4 4.1 ± 3.0 8.6 ± 5.8 81.0 ± 16.0
HCV 49.0 ± 9.1 2 2 25.7 ± 1.1 10.8 ± 3.3 0.9 ± 0.3 1.1 ± 0.4 1.1 ± 0.3 2.7 ± 2.7 70.5 ± 8.7
AIH 47.0 ± 16.8 3 3 25.0 ± 4.2 21.0 ± 14.7 1.4 ± 0.8 2.5 ± 1.7 3.4 ± 2.7 5.0 ± 5.3 66 ± 10.1
PBC 48 1 – 24.2 8 0.8 0.9 1.4 1.3 76
AAT-deficiency 66 1 – 20.2 12 0.6 0.3 0.4 0.6 89
DILI (thioguanine) 48 – 1 28.4 15 0.5 0.6 0.8 0.4 82
Unclear 35 – 1 27.4 10 1.5 2.0 1.5 7.4 95
13 16
NAFLD: non-alcoholic fatty liver disease; PSC: primary sclerosing cholangitis; HCV: hepatitis C virus; AIH: autoimmune hepatitis; PBC: primary biliary cholangitis;
AAT-deficiency: -1-anti-trypsine deficiency; DILI, drug-induced liver injury.
Reference value:
a 3–20 mol/L.
b <0.76 kat/L (in men), <0.61 kat/L (in women).
c <1.1 kat/L (in men), <0.75 kat/L (in women).
d 0.6–1.8 kat/L.
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f 50–90 mol/L (women), 60–100 mol/L (men).
A, USA) followed by a 30 mL saline flush. Image time-
eries were acquired pre- and post-contrast injection (native,
rterial and venous portal phase, 3, 10, 20 and 30 min post-
njection). The delayed and non-enhanced images were captured
sing the following parameters: repetition time = 6.5 ms, echo
ime = 2.3 and 4.6 ms, flip angle = 13◦, typical acquisition
atrix = 168/168, typical FOV = 261 mm × 200 mm ×  342 mm,
lice thickness = 4 mm, slice interval 2 mm, typical imaging
ime = 20.2 s.
The acquired in- and opposed-phase images were recon-
tructed into water and fat images using the inverse gradient
ethod [13–15]. In order to correct for intensity heterogene-
ty in water/fat Dixon images, and to gain reference scaling
hroughout the time-series, the intensity of voxels identified as
ontaining pure adipose tissue was used as an internal reference.
his correction was performed using the multi scale adaptive
ormalizing averaging (MANA) method [16–18].
Quantitative measurements of the uptake of Gd-EOB-DTPA,
efined as KHep and LSC N (10 and 20 min), were performed as
reviously described, [10,11].
.4.  Image  analysis
The qualitative analysis of the bile duct excretion of Gd-
OB-DTPA was based on visual consensus reading of the water
 only images performed by two experienced radiologists (B.N.
nd N.D.) on axial reformats. The readers were blinded to patient
nd time point data as well as histo-pathological findings. Axials
f the 10, 20 and 30 min post-contrast image time-series for all
9 patients were reviewed randomly.Five anatomical regions (peripheral bile ducts in the left and
ight liver lobe, right and left intra hepatic main branch and the
xtra hepatic bile ducts) for each time-series were assessed and
he presence of contrast agent was graded as 1 (‘yes‘) or 0 (‘no’).
3
lThe presence of Gd-EOB-DTPA in each anatomical region
as after the reviewing process summarized on a four graded
cale; 3 = contrast visible at 10 min, 2 = contrast visible at 20 min
ut not at 10 min, 1 = contrast visible at 30 min but not at
0–20 min, 0 = no contrast visible at 10–30 min.
Finally the five scores, one for each anatomical region, as
ell as a total visual score, obtained by adding the five sepa-
ate scores, were related to the histo-pathological findings, the
uantitative contrast agent uptake parameters and blood tests.
.5.  Statistics
Statistical analysis was performed using Stata 12.0 (Stata-
orp, College Station, TX, USA). Results are reported as means
nd standard deviation.
Spearman rank correlation was used to compare visual
ssessment of bile duct excretion of Gd-EOB-DTPA vs. histo-
athological grading of fibrosis, described by the fibrosis score
F0–F4) as well as by a binary variable indicating the presence
r absence of advanced fibrosis or cirrhosis (F3–4), dynamic
ontrast enhancement parameters and liver and renal blood tests.
iagnostic ability of visually assessed bile duct excretion of Gd-
OB-DTPA with respect to the presence or absence of advanced
brosis (F3–4) was performed by calculating the area under the
eceiver operating characteristic curve (AUROC) with a 95%
onfidence interval.
A p value < 0.05 was considered statistically significant.
.  Results.1.  Final  diagnosis  and  ﬁbrosis  scoring
The subject in whom no plausible diagnosis could be estab-
ished prior to liver biopsy had minor histo-pathological changes
22 B. Norén et al. / European Journal of Radiology Open 2 (2015) 19–25
Table 2
Final diagnosis and fibrosis scoring.
Final diagnosis F0 F1 F2 F3 F4
NAFLD 5 – 3 – 1
PSC – 2 2 3 –
HCV – 2 2 – –
AIH 1 2 2 1 1
PBC – – 1 – –
AAT-deficiency – – – 1 –
Total no of subjects 6 6 10 5 2
Data are presented as number of subjects. NAFLD: non-alcoholic fatty liver
disease; PSC: primary sclerosing cholangitis; HCV: hepatitis C virus; AIH:
autoimmune hepatitis; PBC: primary biliary cholangitis; AAT-deficiency: -1-
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Table 4
Diagnostic ability of visually assessed bile duct excretion of Gd-EOB-DTPA
with respect to the presence or absence of advanced fibrosis (F3–4).
AUROC 95% confidence interval
Extra hepatic bile duct 0.67 0.44–0.90
Main duct right liver lobe 0.56 0.32–0.80
Segmental branches right liver lobe 0.51 0.30–0.74
Main duct left liver 0.54 0.29–0.79
Segmental branches left liver lobe 0.55 0.31–0.79
Total visual score 0.54 0.23–0.86
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Snti-trypsine deficiency.
n accordance with autoimmune hepatitis. The patient who took
hioguanine was diagnosed with NAFLD and had no histo-
athological evidence of drug-induced liver injury. In three
atients with suspected autoimmune hepatitis histo-pathological
xamination confirmed this diagnosis. They also showed find-
ngs in accordance with overlap syndrome (one with PBC and
wo with PSC). In the remaining 24 patients liver biopsy con-
rmed the diagnosis. The final diagnosis and fibrosis scoring are
hown in Table 2.
.2.  Analysis  of Gd-EOB-DTPA  excretion
The Gd-EOB-DTPA excretion was visually assessed vs.
istopathology, quantitative contrast uptake parameters and
lood tests. Fig. 1 illustrates the evaluation of the three time
eries.
.2.1. Gd-EOB-DTPA  excretion  vs.  histopathology
No significant correlation between visual assessment of bile
uct excretion of Gd-EOB-DTPA and histo-pathological grad-
ng of fibrosis was found, Table 3. The diagnostic ability of
isually assessed bile duct excretion of contrast is shown in
able 4.
.2.2. Gd-EOB-DTPA  excretion  vs.  quantitative  contrast
ptake parameters
No significant correlation between visual assessment, one
core for each anatomical region as well as a total visual score,
nd the quantified uptake of Gd-EOB-DTPA defined as KHep
nd LSC N was found, see Table 5.
e
M
t
able 3
isual assessment of bile duct excretion of Gd-EOB-DTPA vs. histopathological gra
Extra hepatic
bile duct
Main duct
right liver lobe
Se
br
liv
ibrosis grade (F0–4) −0.34 −0.18 −0
dvanced fibrosis (F3–4) vs. F0–2. −0.30 −0.10 −0
pearman correlation (ρ). No correlations are significant (all p > 0.05).rea under the receiver operating characteristic curve (AUROC) with 95%
onfidence interval.
.2.3.  Gd-EOB-DTPA  excretion  vs.  blood  tests
Concerning correlation between visual assessment and liver
nd renal blood tests significant negative correlations were found
etween ALP and the visual assessment of bile duct excretion
n several anatomic regions see Table 6.
.  Discussion
In this prospective study, with patients without any signs of
irrhosis at the time of inclusion and all patients corresponding
o grade “A” according to the Child–Pugh scoring system, the
ualitative assessment of contrast excretion could not establish a
elationship between the fibrosis grade or contrast uptake param-
ters expressed as KHep or LSC N. In a recent prospective study
owever, where physical examination and laboratory tests like-
ise could not reveal any signs of liver cirrhosis, we found that
iver fibrosis stage strongly influences the hepatocyte-specific
ptake of Gd-EOB-DTPA [11].
The hepatobiliary molecular transport system is complex and
ncludes multiple substrate specific uptake and export proteins
ocated at the hepatocyte sinusoidal and canalicular membranes,
hich differ in their biochemical and functional characteristics.
ile formation is dependent on these mechanisms and dysfunc-
ion at the level of the hepotocyte may result in e.g. cholestasis.
ther reasons for cholestasis are malfunction of the bile secre-
ion and impaired flow in the bile ducts. In order to protect
he hepatocytes from intracellular retention of toxic bile acids
lterations in the transport mechanism may occur [19–21].
Gd-EOB-DTPA is transported over the sinusoidal membrane
ia the organic anion transporting polypeptides OATP1B1 and
ATP1B3. Bidirectional transport is seen within the OATP’s.
d-EOB-DTPA is not metabolized within the hepatocytes andxcreted into the bile through the multidrug resistance protein 2,
RP2. The MRP2 excretion is a unidirectional ATP-dependant
ransporter; moreover MRP2 has a limited rate which in turn
ding of fibrosis.
gmental
anches right
er lobe
Main duct left
liver lobe
Segmental
branches left
liver lobe
Total visual
score
.13 −0.20 −0.12 −0.17
.03 −0.07 −0.08 −0.06
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Fig. 1. Example of Gd-EOB-DTPA excretion in the bile ducts in the tree time series in one F0 patient with the diagnosis of AIH, panels a–c, and two F4 patients
with the diagnosis of AIH and NAFLD, panels d, f and g, i, respectively. In the F0 patient intrahepatic contrast agent is observed at 10 min, indicated with an arrow
in image a. A reduced amount of contrast in central intra hepatic bile ducts was observed between 10 and 20 min. Contrast in the CBD, as indicated with an arrow at
30 min in image c, was observed for all time series (not shown). The difference in contrast excretion between the two F4 patient may be noted – only poorly visible
contrast at 30 min in central intra hepatic bile ducts in patient d–f indicated with arrows in image f.
Table 5
Visual assessment of bile duct excretion of Gd-EOB-DTPA vs. dynamic contrast enhancement parameters.
Extra hepatic
bile duct
Main duct
right liver lobe
Segmental
branches right
liver lobe
Main duct left
liver lobe
Segmental
branches left
liver lobe
Total visual
score
kHep 0.01 0.04 −0.03 0.13 −0.01 −0.03
LSC10 0.07 0.21 0.17 0.30 0.04 0.20
LSC20 0.05 0.21 0.21 0.30 0.07 0.22
LSC N10 0.25 0.24 −0.30 0.30 −0.14 −0.08
L
S
y
a
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a
t
t
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B
A
A
A
A
G
K
SSC N20 0.21 0.23 −0.17 
pearman correlation (ρ). No correlations are significant (all p > 0.05).
ields retention of Gd-EOB-DTPA in the hepatocytes. Located
t the sinusoidal membrane there are two other members of the
RP family, the MRP3 and MRP4, which may be expressed
nd up-regulated under cholestatic conditions returning bile salt
o portal circulation. [21,22]. See Fig. 2.
a
c
c
able 6
isual assessment of bile duct excretion of Gd-EOB-DTPA vs. liver and renal blood 
Extra hepatic
bile duct
Main duct
right liver lobe
Segmental
branches righ
liver lobe
ilirubin 0.19 0.21 0.18 
lbumin 0.07 0.09 0.04 
ST −0.06 −0.02 −0.16 
LT 0.05 0.12 −0.10 
LP −0.42* −0.47* −0.36 
GT −0.18 −0.20 −0.24 
reatinin 0.18 0.21 0.03 
pearman correlation (ρ).
* Significance level, p < 0.05.0.29 −0.09 −0.03
In advanced liver disease such as cirrhosis the uptake sys-
em is likely to be hampered via a number of processes such
s a lower OATP1 activity as described by van Beers et al., a
ompetitively reduced Gd-EOB-DTPA uptake due to high con-
entrations of other metabolites such as bilirubin and a reduced
tests.
t
Main duct left
liver lobe
Segmental
branches left
liver lobe
Total visual
score
0.20 −0.20 0.13
0.06 0.31 0.14
−0.08 −0.20 −0.12
0.13 −0.24 −0.06
−0.42* −0.20 −0.43*
−0.22 −0.08 −0.19
0.22 0.01 0.14
24 B. Norén et al. / European Journal of R
Fig. 2. Uptake of liver specific contrast agent, Gd-EOB-DTPA (‘Gd’), bilirubin
(‘BR’) and bile salts (‘BS’) into hepatocytes. The colored arrows correspond to
direction of transport as the transported molecules and MRP3/4 and MRP2 rep-
resent transporting proteins other than diffusion; MR2 into the bile canaliculus.
The sodium/taurocholate co-transporting polypeptide (NCTP) is also to some
extent involved in the uptake of Gd-EOB-DTPA. The size of the symbols reflects
their relative importance. There is a very strong competition between the con-
trast agent and naturally occurring molecules. Appreciate the many different
possible routes for flux contrast agent into and out of the hepactocytes. Omitted
in this picture is the transporting protein OATP2 which facilitates bile salts and
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specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur
Radiol 2012;22:642–53.
[11] Noren B, Forsgren MF, Dahlqvist Leinhard O, Dahlström N, Kihlbergilirubin transfer into the hepatocyte [18].
mount of hepatocytes. The findings by Tamada et al. of a pro-
onged relative enhancement (RE) of the portal vein and a higher
E of the renal medulla suggest a compensatory increase in the
enal excretion of Gd-EOB-DTPA could support this as well as
he finding by Tschirch et al. of a cut of value for total biliru-
in of ≥30 mol/L for insufficient visualization of the biliary
ree for anatomical diagnosis 20 min after contrast administra-
ion [8,9,22]. But to what extent is the balance between uptake
nd excretion of the contrast agent affected with regard to the
brosis stage?
Is the dominating feature in healthier patients a disturbance
n uptake mechanism and in clinically severe cases a shift toward
 gradually more impaired excretion? Primarily cholestatic dis-
ases such as PSC and PBC will have to be excluded from this
ssumption since they primarily affect the excretion mechanism
nd decreased expression of MRP2 is seen in PBC and PSC
atients [20,23].
Interestingly enough, we found a negative correlation
etween the visual assessment and ALP, elevated levels indi-
ating intra-hepatic cholestasis. Additional statistical analysis,
omparing the sub-group of cholestatic patients (n  = 8), assum-
ng a connection between PSC and PBC and elevated ALP, with
brosis score and Gd-EOB-DTPA dynamic parameters did not
dd additional significant correlation.
In order to further improve the evaluation of the hepatocyte
xcretion pharmaco-dynamics of Gd-EOB-DTPA the following
easures may be considered: (1) to acquire time series with
horter intervals, thereby achieving more detailed information
oncerning contrast timing and characteristics (e.g. 2 min), (2)
o include coronal reformats in the evaluation process and (3)
o increase the flip angle (FA) thereby gaining a stronger T1
eighting and an improved (signal to noise ratio) SNR.adiology Open 2 (2015) 19–25
.  Conclusions
Visually assessed biliary excretion of Gd-EOB-DTPA could
ot establish a relationship between the fibrosis grade or contrast
ptake parameters expressed as KHep or LSC N. However, a
egative correlation between the visual assessment and ALP
as found. The complexity in uptake/excretion mechanism is
ighlighted by the finding in a previous study where liver fibrosis
tage strongly influences the hepatocyte-specific uptake of Gd-
OB-DTPA. Further methodological improvements and larger
rospective studies are desirable.
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